This trial is evaluating whether Tailored Mindfulness Program for Fear of Memory Loss will improve 2 primary outcomes and 5 secondary outcomes in patients with Memory Loss. Measurement will happen over the course of Follow-up (4 weeks).
This trial requires 80 total participants across 2 different treatment groups
This trial involves 2 different treatments. Tailored Mindfulness Program For Fear Of Memory Loss is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Approximately half of men and almost 1/3 of women experience noticeable forgetfulness. However, it is hard to know how many people have or are experiencing memory loss and how common it is for people to find help. As the population ages, it will become important to evaluate the mental wellness of aging people to determine if these complaints are caused by normal aging, age-related medical conditions, or depression. The lack of data on memory loss may be attributed to the fact that people often choose not to report trouble with memory.
This is the first study done in Iran in order to explore the impact of hyperglycemia on spatial memory and attention. The present study revealed that hyperglycemia with diabetes mellitus (DM) is associated with lower attention at the short and longer latency duration interval tests in spatial memory performance, but the results did not meet the criteria for significant significance. Moreover, it was concluded that hyperglycemia was associated with a decline in spatial working memory, but the magnitude and duration of the decline was not significant. The authors suggested that further studies are needed to determine the relationship between spatial memory and hyperglycemia.
There are no specific tests that assess for memory deficits. However, memory impairment in individuals over the age of 50 is often noticeable. For example, memory loss may cause confusion with dementia. Older adults may have difficulty retaining information and putting it to use. Therefore, individuals over the age of 50 should be screened for cognitive decline. This article will offer a systematic approach for screening for older adults with memory complaints.
It is not currently known what causes memory loss. It can occur naturally or be caused by a number of other factors. Because of this, there is research on reversing memory loss, such as the use of a healthy lifestyle.\n
Memory loss is a significant cause of morbidity and mortality in the general age span and can be relieved to some extent by treatment with selective serotonin reuptake inhibitors, antidepressants or dopamine agonists, even after 10 years. Thus, memory loss is not a permanent condition and is not necessarily incurable. While medication is not an effective cure in the long-term, it may improve symptoms in the short-term.
Treatment must be tailored to the individual, and may include medications, physical therapy, and cognitive-behavioral therapy (CBT). Antidepressants are of questionable benefit, and more long-term trials are needed. Patients with significant depression are at risk of further psychological harm or even suicide.
While there is a small group of primary causes of memory loss, a strong correlation was found between two of these and memory loss in the entire group. These factors include smoking, hypertension, hyperglycemia, and hyperlipidemia. The prevalence of memory loss between groups was not significantly different. Primary causes of memory loss have not been previously reported previously in medical literature. This correlation is indicative of possible causal or causal relationships between memory loss and primary disease conditions. One of these conditions may be the result of the other. The exact relationship between memory loss and hypertension needs to be elucidated by further study.
Self-monitoring is only commonly used in combination with other treatments while mindfulness training is not. Both mindfulness and self-monitoring has been proven effective in reducing fear of cognitive decline in healthy elderly.
This pilot study adds further evidence to tailored mindfulness-based self-care program for fear of memory loss. Further studies are necessary to establish the benefits and maintenance of this intervention for a large-group patients.
The present study suggests that there is a strong correlation between an individual's genotype for GABRA5 and their age-related cognitive function. In addition, there was also a strong correlation between GABRA5 rs3212887 genotype and their parents' chronological age, suggesting that there is also a strong familial component for age-related cognitive deficits.
The evidence, as it stands at present, says that there is no evidence that memory loss is a permanent loss. The key factors that determine whether people lose memory are that it is either a progressive deterioration or a functional decline over time. The evidence also suggests that there is scope for improving health care efficiency by reducing the number of people with mild or reversible impairment who are denied treatment unnecessarily.
Memory loss patients with mild to moderate disease had a poor prognosis; however, patients with severe or advanced disease were able to benefit from clinical trials. Thus, memory loss symptoms should not be an absolute contraindication to clinical trial participation for patients with multiple sclerosis.